Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI-1206 with rituximab with or without acalabrutinib in relapsed/refractory indolent B-cell non-Hodgkin lymphoma
2024-512972-36-00Phase 2Authorised
- Sponsor
- BioInvent International
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of BI-1206 in mature B-cell lymphoma, follicular lymphoma (FL), mantle cell lymphoma (MCL) and 1 more (2 arms), sponsored by BioInvent International. Primary endpoints: Safety and tolerability, Maximum tolerated dose and 1 more. Planned start Aug 2024; status: authorised.
02
Drugs
BI-1206
03
Conditions
mature B-cell lymphomafollicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2024-512972-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512972-36-00.